Morgan Stanley
QNCX icon

Morgan Stanley’s Quince Therapeutics QNCX Stock Holding History

Morgan Stanley’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84 Sell
4
-49
-92% -$9.84K ﹤0.01% 7834
2025
Q4 		$35.6K Buy
53
+35
+194% +$17.6K ﹤0.01% 6533
2025
Q3 		$6.01K Sell
18
-4
-18% -$1.33K ﹤0.01% 7046
2025
Q2 		$7.1K Sell
22
-246
-92% -$56.2K ﹤0.01% 6941
2025
Q1 		$71.3K Sell
268
-116
-30% -$35.4K ﹤0.01% 6155
2024
Q4 		$143K Buy
384
+341
+793% +$102K ﹤0.01% 5913
2024
Q3 		$6.62K Hold
43
– – ﹤0.01% 6832
2024
Q2 		$6.39K Buy
43
+1
+2% +$181 ﹤0.01% 6792
2024
Q1 		$8.9K Sell
42
-49
-54% -$12.2K ﹤0.01% 6754
2023
Q4 		$19.1K Buy
91
+43
+90% +$8.61K ﹤0.01% 6676
2023
Q3 		$10.7K Buy
48
+12
+33% +$3.13K ﹤0.01% 6712
2023
Q2 		$10.9K Sell
36
-12
-25% -$3.74K ﹤0.01% 6789
2023
Q1 		$15.1K Sell
48
-11
-19% -$2.15K ﹤0.01% 6735
2022
Q4 		$7.5K Sell
59
-1,074
-95% -$180K ﹤0.01% 7036
2022
Q3 		$302K Sell
1,133
-1,541
-58% -$587K ﹤0.01% 5525
2022
Q2 		$1.19M Sell
2,674
-1,373
-34% -$971K ﹤0.01% 4909
2022
Q1 		$5.01M Sell
4,047
-1,085
-21% -$1.48M ﹤0.01% 3683
2021
Q4 		$13M Buy
5,132
+4,961
+2,901% +$30.3M ﹤0.01% 2637
2021
Q3 		$3.14M Sell
171
-7
-4% -$111K ﹤0.01% 4183
2021
Q2 		$1.89M Buy
178
+71
+66% +$595K ﹤0.01% 4678
2021
Q1 		$773K Sell
107
-701
-87% -$5.04M ﹤0.01% 4889
2020
Q4 		$4.49M Buy
808
+746
+1,203% +$6.61M ﹤0.01% 3376
2020
Q3 		$623K Sell
62
-10
-14% -$90.9K ﹤0.01% 4530
2020
Q2 		$668K Buy
72
+20
+38% +$183K ﹤0.01% 4447
2020
Q1 		$471K Sell
52
-391
-88% -$3.86M ﹤0.01% 4411
2019
Q4 		$4.97M Buy
443
+413
+1,377% +$2.49M ﹤0.01% 3214
2019
Q3 		$148K Sell
30
-202
-87% -$1.24M ﹤0.01% 5287
2019
Q2 		$1.97M Buy
+232
New +$1.39M ﹤0.01% 3780

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley's QNCX Position: Q1 2026 in Review

Morgan Stanley reduced its Quince Therapeutics (QNCX) stake by 92% in Q1 2026, selling an estimated $9.84K and leaving 4 shares worth $84. The position accounts for ﹤0.01% of the portfolio, ranked #7834.

Morgan Stanley first reported a position in QNCX in Q2 2019 and has held it in 28 quarters since. The position peaked at $13M in Q4 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Morgan Stanley held 4 shares of Quince Therapeutics worth $84 as of Q1 2026.
  • Morgan Stanley sold 49 Quince Therapeutics shares in Q1 2026, an estimated $9.84K.
  • Quince Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7834 holding.
  • Morgan Stanley first reported a position in Quince Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Morgan Stanley's Quince Therapeutics position peaked at $13M in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.